Early Results from CYP2C19 Genotype Testing Pilot Mark Landmark for Personalised Stroke Care
The PHG Foundation reports the release of early results from the NHS national pilot for CYP2C19 genotype testing, completed in April 2025. This initiative assesses the feasibility of using genetic testing to guide clopidogrel prescriptions for patients with ischaemic stroke or transient ischaemic attack (TIA). Clopidogrel effectiveness depends on the CYP2C19 enzyme, which is impaired by genetic variants in approximately 30% of the UK population, and over 50% in some ethnic groups. The pilot evaluated both laboratory-based and point-of-care testing methods across four NHS sites between October 2024 and April 2025. These findings underpin the newly released NHS Implementation Guide for CYP2C19 testing, aligning with NICE HealthTech guidance 724. As the first NICE-recommended pharmacogenomics test for a common condition, this development integrates genomic medicine into mainstream cardiovascular care. It addresses critical issues regarding data sharing, clinical decision support, and workforce readiness, aiming to ensure timely and precise prescribing to prevent recurrent strokes.
Wire timeline
Early Results from CYP2C19 Genotype Testing Pilot Mark Landmark for Personalised Stroke Care
The PHG Foundation reports the release of early results from the NHS national pilot for CYP2C19 genotype testing, completed in April 2025. This initiative assesses the feasibility of using genetic testing to guide clopidogrel prescriptions for patients with ischaemic stroke or transient ischaemic attack (TIA). Clopidogrel effectiveness depends on the CYP2C19 enzyme, which is impaired by genetic variants in approximately 30% of the UK population, and over 50% in some ethnic groups. The pilot evaluated both laboratory-based and point-of-care testing methods across four NHS sites between October 2024 and April 2025. These findings underpin the newly released NHS Implementation Guide for CYP2C19 testing, aligning with NICE HealthTech guidance 724. As the first NICE-recommended pharmacogenomics test for a common condition, this development integrates genomic medicine into mainstream cardiovascular care. It addresses critical issues regarding data sharing, clinical decision support, and workforce readiness, aiming to ensure timely and precise prescribing to prevent recurrent strokes.
PHG Foundation